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Abstract The a~c subunit of the L-type calcium channel was 
stable, expressed alone or in combination with the/33 subunit in 
Chinese hamster ovary cells. The /33 subunit enhanced signifi- 
cantly the inactivation of barium currents indicating that both 
subunits interacted with each other. The /]3 subunit decreased 
significantly the half-maximal inhibitory concentration of the cal- 
cium channel blockers (-)-gallopamil and verapamil, but did not 
affect significantly the block caused by isradipine and mibefradil 
at the holding potentials of -80 mV and -40 mV. These results 
suggest hat the/33 subunit affects distinctly the interaction of the 
expressed a~c subunit with different classes of organic calcium 
channel blockers. 
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I. Introduction 
High voltage-activated dihydropyridine sensitive calcium 
channels are complexes of up to three proteins, the cq, az/~ and 
fl subunit [1]. The contribution of the az/~ and the different fl 
subunits to the properties of the native channels is not clear at 
present, The expression of the alc subunit induces L-type cal- 
cium and barium currents (IBa) in CHO and HEK cells. These 
currents have many properties of the native current including 
the sensitivity against organic calcium channel blockers and 
agonists [2-7]. The binding site for dihydropyridines (DHP) 
and phenylalkylamines has been localized exclusively at the al 
subunit [8,9]. In agreement with these biochemical and electro- 
physiological data, expression of the aj subunit alone was suf- 
ficient to restore allosterically regulated high affinity binding 
of isradipine [2,10]. Coexpression of the fll subunit increased in 
parallel the number of binding sites and the density of IBa 
without affecting significantly other DHP binding parameters 
[3]. Recently, it was reported that transient coexpression of the 
fll subunit together with a chimeric al subunit containing the 
amino terminal part of the carp skeletal muscle a~s clone and 
repeat I-IV and the carboxy-terminus of the rabbit cardiac alC-a 
clone in COS cells increased the affinity of the al subunit for 
isradipine over 20-fold [11] suggesting that under some condi- 
tions the fl subunit might affect the affinity of the channel for 
the organic calcium blockers. A drawback of these experiments 
was that no data were provided showing that the expressed cq 
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subunit protein induced L-type current in the COS cells. There- 
fore, we addressed the question whether or not the f13 subunit 
affects significantly the half-maximal concentration of several 
compounds needed to block the current of the expressed CtlC 
subunit. The f13 subunit was choosen since this subunit is ex- 
pressed with the ~c  subunit in vascular smooth muscle, which 
tissue is a therapeutical important arget for the calcium chan- 
nel blockers. 
2. Materials and methods 
2.1. Drugs and reagents 
All chemicals were of the highest purity available. (+)-Verapamil and 
(-)-gallopamil were kindly provided by Knoll AG, Ludwigshafen. (+)- 
Isradipine and mibefradil (Ro 40-5967) were from Sandoz and 
Hoffmann-La Roche, respectively, Basel, Switzerland. The stock solu- 
tion (10 raM) of mibefradil was prepared in bi-distilled water. The stock 
solutions of verapamil, gallopamil and isradipine were prepared in 
ethanol. They were stored at -20°C and diluted to the required concen- 
trations in the extracellular solution. They were always used within a 
day. 
2.2. Cell tran6fection and culture 
The construction and selection of the CHOCal cell line, which con- 
tains the entire protein coding region of the rabbit cardiac qc_ . subunit 
[12], and the CHOC~lfl3 cell line, which expresses the coding region 
of the f13 subunit [13] in addition to the a~ subunit, were described in 
[4,5]. The electrophysiological haracteristics of the CHOCctl cell line 
has been described extensively in [4,5]. An f13 subunit specific peptide 
antibody was raised as described in Ludwig et al. [14]. 
Z3. Electrophysiological recording and data analysis 
The ion currents were recorded under whole-cell patch clamp condi- 
tions [15] using an EPC-9 amplifier (HEKA Elektronik GmbH). Ba 2+ 
was used as a charge carrier and the holding potential was either -80 
or -40 mV. For further details of recording see [5]. The extracellular 
bath solution contained (in mM): NaC1 82, TEA-C1 20, BaCI2 30, CsCI 
5.4, MgCI 2 1, EGTA 0.1, HEPES 5, glucose 10, pH 7.4 (NaOH). The 
intracellular solution contained (in mM): CsC1 102, TEA-CI 10, EGTA 
10, MgC12 1, Naz-ATP 3, HEPES 5, pH 7.4 (CsOH). Drugs were 
applied by a rapid solution changer and reached the cell membrane 
within 1 s [5]. 
The data were analysed by the program package provided by HEKA 
Elektronik. The current-voltage relations were fitted to the Boltzmann 
function: 
I/Im,x = [g(TP - E)]/{1 + exp[ - (TP - V05)/k]} (1) 
where g is the normalized conductance, TP is the amplitude of a test 
pulse, E is the reversal potential, V0. 5 is the half-maximal ctivation 
voltage and k equals the activation slope. The steady-state inactivation 
curves were measured at 0.04 Hz using 5 s conditioning pulses followed 
by a 10 ms return to the holding potential of-80 mV followed by a 150 
ms test pulse to +30 inV. These curves were fitted to the Boltzmann 
equation 2: 
l/Ima x = 1/{1 + exp[- (CP - Vos)/k]} (2) 
where CP is the amplitude of a conditioning prepulse, V05 equals the 
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Fig. 2. Basal biophysical characteristics of the CHOC0~I (cO) and the CHOCoOfl3 (cOil3) cell line. (A) Family of/B, measured in the two (c~l, upper 
part; alfl3, lower part) cell lines. Currents were activated by 100 ms long pulses from the holding potential of -80 mV to the voltages from -20 to 
+ 30 mV, step l0 mV (left part) and from +40 to +70 mV, step 10 mV (right part). Scale bars represent 100 pA and 20 ms. Cell capacity was 17 and 
16 pF. (B) The current-voltage relations for both cell lines. Each individual l/V curve was normalized to the maximal inward current (peak l/V) and 
all normalized IIV curves were then averaged. The lines were obtained by fitting the points to the Eqn. 1 with following values: ~1 cell line: 
g=0.026+0.001, V05 =14.6 _+ 0.3, E=70.2_+0.4, k=7.4+0.2,  2,2=0.00013, n= 11. c~lfl3 cell line: g=0.027+0.001, V05=11.5+0.6 , 
E -- 66.0 _+ 0.5, k = 7.2 + 0.3,2 "2 = 0.00045, n = 16. The inward currents activated by the depolarizing pulses to 0, +10 and +50 mV were significantly 
different in both cell lines. (C) The time courses of the IBa inactivation measured uring a 800 ms long depolarizing pulse from the holding potential 
-80 mV to +30 inV. Traces were superimposed to facilitate a comparison. The transposed lines represent fits by the sum of two exponentials. 
Corresponding time constants are: ~1 cell, rl = 260 ms, r2 = 2.70 s, cell capacity 14 pF; ~lf13 cell, rl = 140 ms, r2 = 0.92 s, cell capacity 16 pF. 
Calibration bars represent (horizontal) 100 ms and (vertical) 50 pA for both c~l and elfl3. (D) The steady-state inactivation (SSI) curves for individual 
cells were measured as described in section 2. Each individual SSI curve was normalized to the maximal inward current measured uring the test 
pulse. All normalized curves were then averaged. The lines were obtained by fitting the points to the Eqn. 2 with following values: ~1 cell line, 
Vo. 5 = -3.2 _+ 1.3, k = 11.2 + 0.9, n = 9; 0~lf13 cell line, V~. s= -8.4 + 0.8, k = 9.4 + 0.L n = 13. 
half-maximal inactivation voltage and k is the inactivation slope. The 
dose-dependence curves were fitted to the Hill equation (3): 
1lima x = 100/[1 + (conc/ICs0) n] (3) 
where conc is the concentration f an investigated drug, IC50 is the drug 
concentration that suppresses the current amplitude by 50% and n is 
the Hill coefficient. If not mentioned otherwise, all values are 
means + S.E.M. with the number of cells in brackets. The significance 
of difference between two sets of observations was evaluated by un- 
paired Student's t-test. 
3. Results and discussion 
3.1. Coexpression of the ft3 subunit affects 18, 
The CHOCcO and the CHOCcOft3 cells had the characteris- 
tic current of an L-type calcium channel (Fig. 2A) (see also 
[4,5]). The expression of the ft3 subunit protein in the 
CHOCcOft3 cells was confirmed by an immunoblot using anft3 
specific antibody (Fig. 1). Both cell lines bound similar amounts 
of isradipine (between 73. 5 and 99 fmol/mg in four different 
anti- 3 
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Fig. 1. Expression of theft3 protein. Microsomal membranes (50Bg per 
lane) of a non-transfected CHO cell (CHO-) and CHOCalfl3 cell 
(CHO~ro023) were separated on a 7.5% SDS gel and transferred to an 
immobilon membrane. The blot was probed with an f13 subunit specific 
antibody and stained by a second alkaline phosphatase coupled anti- 
rabbit IgG antibody. 
membrane preparations) with the same affinity (Kd between 
0.15 and 0.2 nM). Thef  subunit was functional coupled to the 
~ subunit as indicated by several changes of the IBa kinetics 
(Fig. 2), although the density of IBa was not significantly altered 
in the presence of the ft3 subunit (Table 1). To compare voltage- 
dependent activation of IBa in both cell lines, the curren~vol- 
rage relation of individual cells were normalized to the maximal 
inward current, averaged and fitted to the Eqn. 1 (see section 
2). The average half-maximal activation voltage was shifted by 
3.2 mV in the hyperpolarizing direction upon ft3 coexpression 
(Fig. 2B). The speed of the current inactivation during an 800 
ms long depolarizing pulse to +30 mV was significantly en- 
hanced in the presence of the ,83 subunit (Fig. 2C). The time 
course of the I~  inactivation could be best fitted by the sum 
of two exponentials. The two time constants were significantly 
different between the two cell lines (Table 1). Furthermore, the 
ft3 subunit shifted the half-maximal inactivation voltage by 5.2 
mV to hyperpolarizing potentials (Fig. 2D and Table 1). Both 
steady-state inactivation curves were significantly different at 
the conditioning potentials positive to -20 mV at P<0.05 or 
better (Fig. 2D). These results strengthened the notion that the 
ft3 subunit affected inactivation and activation of the channel 
but had no effect on the density of IB, or DHP binding sites. 
These findings are in line with previous studies which had 
shown a wide variability of the regulatory effects of the coex- 
pression of a f t  subunit on the kinetics of the expressed cq 
subunit [6,16,18]. 
3.2. The ft3 subunit modifies the &teraction of  calcium channel 
blockers with the eric_ . subunit 
The inhibitory potency of the different calcium channel 
blockers was tested at holding potentials of -80 mV and -40 
mV in both cell lines - examples of individual traces are given 
in Fig. 3 because these drugs block the L-type calcium channel 
voltage-dependent [4-6,19,20]. At a holding potential of -80 
mV, the f13 subunit did not affect significantly the ICs0 values 
for isradipine, a DHP, which were 25 nM and 20 nM in the 
absence and presence of the ft subunit, respectively (Fig. 4A and 
Table 2). A shift in the holding potential from -80 mV to -40 
mV increased the affinity for isradipine 9- and 20-fold in the 
CHOC~zl and CHOCcOft3 cells, respectively. The difference 
between the ICs0 values at a holding potential of -40 mV was 
not significant at a P<0.05 level indicating that the ft3 subunit 
did not affect significantly the affinity for isradipine. These 
results are in agreement with earlier findings and suggestions 
that the affinity of the channel for this organic blocker depends 
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only on the ~l subunit [4-6,10] and is not increased by the 
coexpression of a fl subunit. 
The above experiments were repeated with the phenylal- 
kylamine verapamil. Surprisingly, the fl subunit increased the 
affinity for verapamil 2.6- and 13.6-fold at holding potential 
-80 mV and -40 mV, respectively (Fig. 4C and Table 2). 
Verapamil is known to interact with several proteins in a semi- 
specific manner. To rule out 'non-specific' interactions of vera- 
pamil, the (-)-isomer of gallopamil was included in this study. 
At both holding potentials, the block by (-)-gallopamil was 
significantly enhanced in the presence of the 133 subunit, al- 
though the effect of the fl subunit was less pronounced than 
with verapamil (Fig. 4B). The fl subunit shifted the ICs0 values 
for (-)-gallopamil 2.7-fold at both holding potentials (Table 2). 
These results suggested that the f13 subunit affected the affin- 
ity for phenylalkylamines but not that for the dihydropyridine. 
To test the potential generality of this observation, the experi- 
ments were extended to include mibefradil, an organic alcium 
channel blocker which does not belong to the used two classes 
of calcium channel blockers. Mibefradil blocks high and low 
<.... 
Fig. 3. Example of currents recorded in the absence and presence of the 
indicated rug concentrations in both cell lines at both holding poten- 
tials. In each pair of traces, the control trace was recorded just before 
the superfusion with the indicated rug started. The second trace shows 
IBa 3 min after drug application, when a new stable current amplitude 
was reached. The IB, was activated by 40 ms long pulse from the holding 
potential -80 mV to +30 mV, or from the holding potential -40 mV 
to +30 mV with the frequency of 0.2 Hz. Calibration bars represent 10 
ms (horizontal) and 100 pA (vertical). 
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Fig. 4. Dose response curves for isradipine (A), (-)-gallopamil (B), verapamil (C) and mibefradil (D). The IBa was activated by 40 ms long pulse 
from the holding potential -80 mV to +30 mV, or from the holding potential -40 mV to +30 mV with the frequency of 0.2 Hz. After the steady-state 
currents were reached in the presence of drug, the 'equilibrated' amplitude of the inward current in the presence of the drug was normalized to the 
amplitude in the absence of the drug. Between 5and 10 measurements in different cells were averaged at each drug concentration a d holding potential. 
The points were fitted to the equation 3. The Hill coefficients were not fixed in equation 3 and varied from 0.6 to 1.2 in individual curves. 
voltage-activated calcium channels [21] and inhibits the current 
through all cloned and expressed high voltage-activated cal- 
cium channels with similar affinity [22] suggesting a common 
blocking mechanism. In both cell lines mibefradil blocked IRa 
at each holding potential (Fig. 4D). However, the coexpression 
of theft3 subunit had no significant effect on the extent of block 
at all investigated concentrations (Table 2) suggesting that the 
f13 subunit affected rather drug specific the block of the cq 
subunit. In this context it is of interest that the /3  subunit 
interacts with the ~, subunit at the intracellular loop connecting 
repeat I and II [23] and that phenylalkylamines block the chan- 
nel from the cytosol [24] and bind potentially to the intracellular 
side of the cq subunit at the IVS6 segment [9], whereas the 
DHPs approach the channel from the extracellular space [25]. 
Table 1 
Basic electrophysiological haracteristics of the two cell lines 
Cell Inactivation time constants 
/max rl r2 I/o.5 
(pA/pF) (ms) (s) (mV) 
CHOC~I - l l .3  + 1.3 254 + 20* 2.8 --_ 0.4*** -3.2 + 1.3 
(11) (11) (11) (9) 
CHOC0~lfl3 -13.8 _+ 1.7 166 __ 14" 0.90 + 0.07*** -8.4 __ 0.8 
(16) (16) (16) (13) 
Lna~ for each cell was calculated from the peak current of individual 
current-voltage relations and was normalized to the cell capacity. The 
inactivation time constants r l and v2 were calculated from the double- 
exponential fits to the current races measured uring 800 ms depolar- 
izing pulse from holding potential -80 mV to +30 mV. V0. 5 is the 
half-maximal inactivation voltage calculated according to the Eqn. 2. 
* and ***Indicate a significant difference between the two cell lines at 
P < 0.05 and P < 0.001, respectively. 
Table 2 
Inhibitory constants for various calcium channel blockers 
Compound Holding IC50 ~M)  P_< 
potential 
(mV) CHOCal CHOC~Ifl3 
lsradipine -80 0.025 + 0.002 0.020 + 0.004 n.s. 
-40 0.0027 + 0.0010 0.001 + 0.001 n.s. 
Gallopamil -80 51 + 4 23 + 4 0.01 
-40 3.7 + 0.3 1.1 + 0.2 0.001 
Verapamil -80 225 _+ 60 84 _+ 15 0.05 
-40 15 + 3 1.1 + 0.2 0.01 
Mibefradil -80 4.9 + 0.7 4.3 + 0.3 n.s. 
-40 1.4 + 0.3 0.9 _+ 0.1 n.s. 
For experimental details see legends to Figs. 3 and 4. The dose-re- 
sponse curves were fitted to Eqn. 3. The P values how non-significant 
(n.s.) and significant differences between the IC50 values of both cell 
lines. 
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The mechanism by which the fl subunit affected the efficacy 
of the phenylalkylamines block is unknown. It is tempting to 
attribute the enhanced sensitivity to phenylalkylamines to the 
increased availability of the channel in the inactivated state, 
which should facilitate their interaction with the blockers. 
However, in this case one would expect an increased sensitivity 
of the channels towards the block by isradipine and mibefradil, 
too. On the other hand, a major conformational change of the 
phenylalkylamine binding site caused by the interaction of the 
fl subunit with the c~1 subunit is unlikely, since theft subunit had 
no effect on the efficacy of the two other calcium channel 
blockers. A direct verification of this hypothesis was not possi- 
ble, since non-transfected CHO cells have already a high affin- 
ity binding site for phenylalkylamines [6]. Therefore ven if the 
above mechanism was not excluded, it can not be the only one 
responsible for the altered sensitivity of channel to the phenylal- 
kylamine blockers either. It is more likely that the increase in 
blocking efficiency was caused by subtle changes in the basic 
biophysical properties of the channel. The binding of the fl 
subunit o the cq subunit shifts the voltage for channel opening 
to negative membrane potentials [26]. One may expect here- 
fore, regulatory effects of the binding of the fl subunit on other 
regions of the st subunit including the binding sites for organic 
calcium channel blockers. This interpretation is supported by 
the recent finding that the use of alternative xons of the Cqc 
gene, which are not involved in the areas identified as direct 
binding sites [9], has a marked effect on the efficacy of nisoldip- 
ine [4] and isradipine [27] as channel blockers. The results of 
this report ogether with these previous observations indicates, 
therefore, that the half-maximal inhibitory concentration of a 
specific compound is not only determined by the residues lo- 
cated at the binding site, but also by residues far apart from the 
binding site which affect he biophysical properties of the channel. 
Acknowledgements: This work was supported by grants from Deutsche 
Forschungsgemeinschaft andFond der Chemie. 
References 
[1] Hofmann, F., Biel, M. and Flockerzi, V. (1994) Annu. Rev. Neu- 
rosci. 17, 399-418. 
[2] Bosse, E., Bottlender, R., Kleppisch, T., Hescheler, J. Welling, A., 
Hofmann, F. and Flockerzi, V. (1992) EMBO J. 11, 2033-2038. 
[3] Welling, A., Bosse, E., Cavali6, A., Bottlender, R., Ludwig, A., 
Nastainczyk, W., Flockerzi, V. and Hofmann, F. (1993) J. Physiol. 
474, 749-765. 
[4] Welling, A., Kwan, Y.W., Bosse, E., Flockerzi, V., Hofmann, F. 
and Kass, R.S. (1993) Circ. Res. 73, 974-980. 
[5] Lacinova, L., Welling, A., Bosse, E., Ruth, P., Flockerzi, V. and 
Hofmann, F. (1995) J. Pharmacol. Exp. Ther. 274, 54-63. 
[6] Welling, A., Lacinova, L., Donatin, K., Ludwig, A., Bosse, E., 
Flockerzi, V. and Hofmann, F. (1995) Pfliigers Arch. 429, 400- 
411. 
[7] P6rez-Garcia, M., Kamp, T. and Marban, E. (1995) J.Gen.Physiol. 
105, 289-306. 
[8] Regulla S., Schneider, T., Nastainczyk, W., Meyer, H.E. and 
Hofmann, F. (1991) EMBO J. 10, 4549. 
[9] Catterall, W.A. and Striessnig, J. (1992) Trends Pharmacol. Sci. 
13, 256-262. 
[10] Kim H.S., Wie, X., Ruth, P., Perez-Reyes, E., Flockerzi, V., 
Hofmann, F. and Birnbaumer, L. (1990) J. Biol. Chem. 265, 
11858-11863. 
[11] Mitterdorfer, J. Froschmayr, M., Grabner, M., Striessnig, J. and 
Glossmann, H. (1994) FEBS Lett. 352, 141-145. 
[12] Biel, M., Hullin, R., Freundner, St., Singer, D., Dascal, N., Flock- 
erzi, V. and Hofmann, F. (1991) Eur. J. Bioehem. 200, 81-88. 
[13] Hullin, R., Singer-Lahat, D., Freichel, M., Biel, M., Dascal, N., 
Hofmann, F. and Flockerzi, V. (1992) EMBO J. 1l, 885-890. 
[14] Ludwig, A., Bosse, E., Brandt, W., Flockerzi, V. and Hofmann, 
F. (1994) Naunyn-Schmiederberg's Arch. Pharmacol. 349S, R40. 
[15] Hamill, O. P., Marty, E., Neher, E., Sakmann, B. and Sigworth, 
F.J. (1981) Pfliigers Arch. 391, 85-100. 
[16] Olcese, R., Qin, N., Schneider, T., Neely, A., Wie, X., Stefani, E. 
and Birnbaumer, L. (1994) Neuron 13, 1433-1438. 
[17] De Waard, M. and Campbell, K.R (1995) J. Physiol. 485, 619- 
634. 
[18] Ellinor,P. T., Zhang, J.-F., Randall, A.D., Zhou, M., Schwarz, 
T.L., Tsien, R.W. and Horne, W.A. (1993) Nature 363, 455-458. 
[19] Sanguinetti, M.C. and Kass, R.S. (1984) Circ. Res. 55, 336- 
348. 
[20] Bean, B.P. (1984) Proc. Natl. Acad. Sci. USA 81, 6388-6392. 
[21] Mehrke, G., Zong, X.G., Flockerzi, V. and Hofmann, F. (1994) 
J. Pharmacol. Exp. Ther. 271, 1483 1488. 
[22] Bezprozvanny, I. and Tsien, R.W. (1995) Biophys. J. 68(2), A260. 
[23] Pragnell, M., De Waard, M., Mori, Y., Tanabe, T., Snutch, T.P. 
and Campbell, K. (1994) Nature 9368, 67--70. 
[24] Hescheler, J., Pelzer, D., Trube, G. and Trautwein, W. (1982) 
Pfliigers Arch. 393, 387-291. 
[25] Bangalore, R., Baindur, N., Rutledge, A., Triggle, D.J. and Kass, 
R.J. (1994) Mol. Pharmacol. 46, 660-666. 
[26] Neely, A., Wie, X., Olcese, R., Birnbaumer, L. and Stefani, E. 
(1993) Science 262, 575-578. 
[27] Soldatov N.M., Bouron, A. and Reuter, H. (1995) J. Biol. Chem. 
270, 10540-10543. 
